Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

25 February 2020

Could China's coronavirus outbreak hurt the global drug industry?

Elize Mak of Al Jazeera reports on the concerns of possible shortages of antibiotics following the coronavirus outbreak. Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, is quoted on the impact that the virus could have on the global supply of these lifesaving products.

Direct links

Read the full article

The article uncovers the possibility of global antibiotic shortages if manufacturers of key ingredients in China remain affected by government measures to contain the virus. 

Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation is quoted in the article:

"It would be very difficult for a foreign buyer to replace Chinese API supplies in the event of a disruption - at least not quickly. What's more patients are typically given inferior drugs during shortages."

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved